C. Marcelo Aldaz

Dr. C. Marcelo Aldaz

Department of Epigenetics & Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, South Campus Research, Building 4 (4SCR4.1037), 1901 East Road, Unit 1951, Houston, TX 77054, USA
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2003 in Bioinformatics
Verified
Journal Article
Open access
PDF file
KBKeith A. Baggerly
Keith A. Baggerly
LDLi Deng
Li Deng
JMJeffrey S. Morris
Jeffrey S. Morris
CAC. Marcelo Aldaz
C. Marcelo Aldaz
Motivation: In contrasting levels of gene expression between groups of SAGE libraries, the libraries within each group are often combined and the counts for the tag of interest summed, and inference is made on the basis of these larger ‘pseudolibraries’. While this captures the sampling variability inherent in the procedure, it fails to allow for normal variation in levels of the gene between individuals within the same group, and can consequently overstate the significance of the results. The effect is not slight: between-library variation can be hundreds of times the within-library variation. Results: We introduce a beta-binomial sampling model that correctly incorporates both sources of variation. We show how to fit the parameters of this model, and introduce a test statistic for differential expression similar to a two-sample t-test. Contact: kabagg@mdanderson.org Supplementary information http://bioinformatics.mdanderson.org/ Includes Matlab and R code for fitting the model.

2 March 2011 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
CTC. Thangavel
C. Thangavel
JDJ. L. Dean
J. L. Dean
AEA. Ertel
A. Ertel
KKK. E. Knudsen
K. E. Knudsen
CAC. Marcelo Aldaz
C. Marcelo Aldaz
EKE. S. Knudsen
E. S. Knudsen
The majority of estrogen receptor (ER)-positive breast cancers are treated with endocrine therapy. While this is effective, acquired resistance to therapies targeted against ER is a major clinical challenge. Here, model systems of ER-positive breast cancers with differential susceptibility to endocrine therapy were employed to define common nodes for new therapeutic interventions. These analyses revealed that cell cycle progression is effectively uncoupled from the activity and functional state of ER in these models. In this context, cyclin D1 expression and retinoblastoma tumor suppressor protein (RB) phosphorylation are maintained even with efficient ablation of ER with pure antagonists. These therapy-resistant models recapitulate a key feature of deregulated RB/E2F transcriptional control. Correspondingly, a gene expression signature of RB-dysfunction is associated with luminal B breast cancer, which exhibits a relatively poor response to endocrine therapy. These collective findings suggest that suppression of cyclin D-supported kinase activity and restoration of RB-mediated transcriptional repression could represent a viable therapeutic option in tumors that fail to respond to hormone-based therapies. Consistent with this hypothesis, a highly selective CDK4/6 inhibitor, PD-0332991, was effective at suppressing the proliferation of all hormone refractory models analyzed. Importantly, PD-0332991 led to a stable cell cycle arrest that was fundamentally distinct from those elicited by ER antagonists, and was capable of inducing aspects of cellular senescence in hormone therapy refractory cell populations. These findings underscore the clinical utility of downstream cytostatic therapies in treating tumors that have experienced failure of endocrine therapy. Abstract The majority of estrogen receptor (ER)-positive breast cancers are treated with endocrine therapy. While this is effective, acquired resistance to therapies targeted against ER is a major clinical challenge. Here, model systems of ER-positive breast cancers with differential susceptibility to endocrine therapy were employed to define common nodes for new therapeutic interventions. These analyses revealed that cell cycle progression is effectively uncoupled from the activity and functional state of ER in these models. In this context, cyclin D1 expression and retinoblastoma tumor suppressor protein (RB) phosphorylation are maintained even with efficient ablation of ER with pure antagonists. These therapy-resistant models recapitulate a key feature of deregulated RB/E2F transcriptional control. Correspondingly, a gene expression signature of RB-dysfunction is associated with luminal B breast cancer, which exhibits a relatively poor response to endocrine therapy. These collective findings suggest that suppression of cyclin D-supported kinase activity and restoration of RB-mediated transcriptional repression could represent a viable therapeutic option in tumors that fail to respond to hormone-based therapies. Consistent with this hypothesis, a highly selective CDK4/6 inhibitor, PD-0332991, was effective at suppressing the proliferation of all hormone refractory models analyzed. Importantly, PD-0332991 led to a stable cell cycle arrest that was fundamentally distinct from those elicited by ER antagonists, and was capable of inducing aspects of cellular senescence in hormone therapy refractory cell populations. These findings underscore the clinical utility of downstream cytostatic therapies in treating tumors that have experienced failure of endocrine therapy.

19 May 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NYNeelu Yadav
Neelu Yadav
JLJaeho Lee
Jaeho Lee
JKJeesun Kim
Jeesun Kim
JSJianjun Shen
Jianjun Shen
MHMickey C.-T. Hu
Mickey C.-T. Hu
MBMark T. Bedford
Mark T. Bedford
Arginine methylation has been implicated in the regulation of gene expression. The coactivator-associated arginine methyltransferase 1 (CARM1/PRMT4) binds the p160 family of steroid receptor coactivators (SRCs). This association enhances transcriptional activation by nuclear receptors. Here, we show that embryos with a targeted disruption of CARM1 are small in size and die perinatally. The methylation of two known CARM1 substrates, poly(A)-binding protein (PABP1) and the transcriptional cofactor p300, was abolished in knockout embryos and cells. However, CARM1-dependent methylation of histone H3 was not observed. Furthermore, estrogen-responsive gene expression was aberrant in Carm1 – / – fibroblasts and embryos, thus emphasizing the role of arginine methylation as a transcription activation tag. These findings provide genetic evidence for the essential role of CARM1 in estrogen-mediated transcriptional activation.

16 July 1998 in Oncogene
Verified
Journal Article
Closed access
ABAndrew J Brenner
Andrew J Brenner
MSMartha R Stampfer
Martha R Stampfer
CAC. Marcelo Aldaz
C. Marcelo Aldaz

1 April 1995 in Genes & Development
Verified
Journal Article
Open access
PDF file
LDL A Donehower
L A Donehower
LGL A Godley
L A Godley
CAC. Marcelo Aldaz
C. Marcelo Aldaz
RPR Pyle
R Pyle
YSY P Shi
Y P Shi
HVH E Varmus
H E Varmus
By crossing mice that carry a null allele of p53 with transgenic mice that develop mammary adenocarcinomas under the influence of a Wnt-1 transgene, we have studied the consequences of p53 deficiency in mammary gland neoplasia. In Wnt-1 transgenic mice homozygous for the p53 null allele, tumors appear at an earlier age than in animals heterozygous or wild-type at the p53 locus. About half of the tumors arising in p53 heterozygotes exhibit loss of the normal p53 allele, implying selection for p53-deficient cells. Mammary tumors lacking p53 display less fibrotic histopathology and increased genomic instability with aneuploidy, amplifications, and deletions, as detected by karyotype analysis and comparative genomic hybridization. In one tumor, the amplified region of chromosome 7 had an ectopically expressed int-2/FGF3 proto-oncogene, a gene known to cooperate with Wnt-1 in the production of mammary tumors. These findings favor a model in which p53 deficiency relaxes normal restraints on chromosomal number and organization during tumorigenesis.

15 April 2000
Verified
Journal Article
Closed access
ABAndrzej Bednarek
Andrzej Bednarek
KLK J Laflin
K J Laflin
RDR L Daniel
R L Daniel
QLQ Liao
Q Liao
KHK A Hawkins
K A Hawkins
CAC. Marcelo Aldaz
C. Marcelo Aldaz